Company intelligence / Profile preview

Crestovo

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Developed CP101, an oral full-spectrum microbiota therapeutic showing positive Phase 2 results (74.5% sustained clinical cure at 8 weeks in PRISM3 trial) for preventing recurrent CDI; program advanced post-merger but later discontinued by parent company.

Therapeutic areas: Infectious Diseases
Modalities: Live biotherapeutic product therapy
Industry: Biotech

Partnerships

Takeda Pharmaceutical Company Limited

Beyond the preview

Go deeper on Crestovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crestovo.

Explore the full profile